About VistaGen

About VistaGen

VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to set a new and better standard of care for the treatment of anxiety, depression and other central nervous system (CNS) disorders. Our CNS pipeline includes three product candidates, PH94B, PH10 and AV-101, each with a differentiated profile, favorable safety results observed in all clinical studies to date, and therapeutic potential in multiple CNS indications.

Key elements of our corporate strategy include:

  • Focus on highly prevalent anxiety, depression and neurological disorders affecting both adult and pediatric populations where the current standard of care is inadequate to meet patient needs.
  • Emphasize development and commercialization of CNS product candidates with potential for rapid-onset therapeutic effects, exceptional safety and tolerability, and significant commercial potential in multiple CNS indications in global markets with currently limited or inadequate treatment options;
  • Continue internal research and development efforts to evaluate the expanded therapeutic and commercial potential for our existing CNS product candidates in the treatment of additional CNS indications and identify additional CNS drug candidates for our CNS product portfolio;
  • Pursue global development, on our own in the U.S. and on our own or with collaborators outside the U.S., of novel CNS product candidates which are fundamentally differentiated from currently approved therapies; and
  • Commercialize on our own, and retain all commercial rights to, our CNS product candidates in the U.S. and partner with highly qualified third-party collaborators for commercialization of our CNS product candidates outside the U.S.

Our Leadership

Our executive team is made up of visionary thinkers and experts, dedicated to positioning VistaGen for long-term success.

Shawn K. Singh, J.D. photo
Shawn K. Singh, J.D.
Chief Executive Officer and Director
H. Ralph Snodgrass, Ph.D. photo
H. Ralph Snodgrass, Ph.D.
President and Chief Scientific Officer
Mark A. Smith, M.D., Ph.D. photo
Mark A. Smith, M.D., Ph.D.
Chief Medical Officer
Ann Cunningham, MBA photo
Ann Cunningham, MBA
Chief Commercial Officer and Director
Jerrold D. Dotson, CPA photo
Jerrold D. Dotson, CPA
Vice President, Chief Financial Officer and Secretary